Abstract
Human Papilloma Virus (HPV) is the most common sexually transmitted disease with over 14 million infections in 2008. Certain HPV types have been identified in up to 70% of cases of cervical and anal cancers. Despite being safe and effective, HPV vaccination rates remain low. Vaccination and demographic data was collected pre-and post-intervention. Among 13 thru 17-year-old cohort females were significantly more likely to be fully vaccinated. Assessment also found that patients insured by Medicaid were significantly more likely to be fully vaccinated than patients insured privately. Post-intervention vaccination rate is similar to baseline rates. There was non-significant improvement in HPV vaccination coverage after intervention. Male and privately insured patients of Creighton’s Pediatric Clinic have lower HPV vaccination coverage than their counterparts. More direct efforts are needed in vaccination process and policy in the clinic to improve immunization against HPV among children and adolescents.
Similar content being viewed by others
References
Bosch, F. X., Broker, T. R., Forman, D., et al. (2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31 (Supplement 7(0)), H1–H31.
Palefsky, J., & Cranston, R. Virology of human papillomavirus infections and the link to cancer. http://www.uptodate.com. Updated October 15, 2014.
Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. The New England Journal of Medicine, 338(7), 423–428.
de Sanjose, S., et al. (2010). Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncology, 11(11), 1048–1056.
Markowitz, L. E., Dunne, E. F., Saraiya, M., et al. (2014). Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendations Report, 63(-05), 1–30.
Curtis, C. R., et al. (2014) National human papillomavirus vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2011. MMWR Surveillance Summary, 63 (suppl 2), 61–70.
Stier, E. A., Sebring, M. C., Mendez, A. E., et al. (2015). Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: A systematic review. The American Journal of Obstetrics & Gynecology, 213, 278–309.
Meites, E. (2016) Use of a 2-dose schedule for human papillomavirus vaccination—Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and Mortality Weekly Report, 65(49), 1405–1408.
Rahman, M., Hirth, J. M. & Berenson, A. B. (2017). Adherence to ACIP recommendation for human papillomavirus vaccine among US adolescent girls. Journal of Community Health, 42(2), 385–389.
Farias, C. C., et al. (2016). Factors related to non-compliance to HPV vaccination in Roraima—Brazil: A region with a high incidence of cervical cancer. BMC Health Services Research, 16(1), 417.
Joura, Elmar A., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711–723.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Varman, M., Sharlin, C., Fernandez, C. et al. Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention. J Community Health 43, 455–458 (2018). https://doi.org/10.1007/s10900-018-0467-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10900-018-0467-3